Please login to the form below
Enerzair Breezhaler
This page shows the latest Enerzair Breezhaler news and features for those working in and with pharma, biotech and healthcare.
Novartis reveals full phase 3 results for Enerzair Breezhaler
Asthma treatment received EU approval earlier this week. Novartis has published the full results from the phase 3 IRIDIUM study of its Enerzair Breezhaler in patients with uncontrolled asthma. ... The overall occurrence of adverse events and serious
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Latest Intelligence
-
On our best behaviour
Novartis entered a partnership with Propeller to utilise the company’s sensor for the Enerzair Breezhaler inhaler, where it can collect medication data and send that information to a corresponding app.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn
- Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas
- UK-India research project trialling easy-to-use UTI test to support fight against AMR
- Cancer Research UK and Guardant collaborate to advance cancer detection and treatment
- Give the gift of positive change
- Apple Vision Pro: challenges and opportunities for pharma
No results were found
PMHub
Create Health
A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
